scPharmaceuticals’ (NSDQ:SCPH) has signed a development agreement to incorporate West Pharmaceutical Services’(NYSE:WST) SmartDose drug delivery system with Furoscix, a drug that scPharmaceuticals developed to treat edema in heart failure patients.
Burlington, Mass.-based scPharmaceuticals recently completed preliminary feasibility studies of the drug-device combination. The testing included drug stability in the pre-filled cartridge, drug compatibility, and overall performance within Furoscix-delivery specifications. Previously FDA-approved SmartDose allows patients to self-administer medication in accordance with their prescribed treatment. It adheres to the patient’s body, enabling hands-free administration.